Neuroblastoma with high ASPM reveals pronounced heterogeneity and poor prognosis.
ASPM
Metabolic heterogeneity
Neuroblastoma
Prognosis
Risk stratification
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
17 Sep 2024
17 Sep 2024
Historique:
received:
22
11
2023
accepted:
06
09
2024
medline:
18
9
2024
pubmed:
18
9
2024
entrez:
17
9
2024
Statut:
epublish
Résumé
We explored the preliminary value of abnormal spindle-like microcephaly- associated (ASPM) protein in aiding precise risk sub-stratification, prediction of metabolic heterogeneity, and prognosis of neuroblastoma (NB). This retrospective study enrolled newly diagnosed patients with NB who underwent positron emission tomography/computed tomography (PET/CT) before therapy, and tumor tissue was collected after surgery. Regression analysis was used to evaluate ASPM expression and risk stratification in patients with NB. The expression levels of ASPM, clinical information, and PET/CT text features were analyzed using univariate and multivariate survival analyses. Finally, a correlation analysis was used to explore the relationship between ASPM and tumor metabolic heterogeneity. There were 48 patients with NB in this study (35 boys and 13 girls); 22 patients progressed and 16 died. We found that the level of ASPM was highly associated with risk stratification (OR = 5.295, 95%IC: 1.348-41.722, p = 0.021). Patients with NB and high-risk stratification with high ASPM level had a lower 3-year progression-free survival (PFS) rate (14.28%) and 1-year PFS rate (57.14%) than those with low ASPM level (57.14% and 93.75%, respectively). Using univariate and multivariate survival analyses, this study revealed that ASPM and LDH were independent risk factors for both PFS and overall survival (OS), whales GLZLM_ZLNU was only a risk factor for PFS. ASPM holds promise as a novel biomarker for refining current risk stratification and predicting prognosis in neuroblastoma. Elevated levels of ASPM, LDH, and GLZLM_ZLNU may be associated with poorer survival outcomes in neuroblastoma patients.
Identifiants
pubmed: 39289658
doi: 10.1186/s12885-024-12912-4
pii: 10.1186/s12885-024-12912-4
doi:
Substances chimiques
ASPM protein, human
0
Biomarkers, Tumor
0
Nerve Tissue Proteins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1151Subventions
Organisme : National Natural Science Foundation of China
ID : 81901775
Organisme : National Natural Science Foundation of China
ID : 81801731
Informations de copyright
© 2024. The Author(s).
Références
Berbegall AP, Villamon E, Piqueras M, Tadeo I, Djos A, Ambros PF, Martinsson T, Ambros IM, Canete A, Castel V, Navarro S, Noguera R. Comparative genetic study of intratumoral heterogenous MYCN amplified neuroblastoma versus aggressive genetic profile neuroblastic tumors. Oncogene. 2016;35:1423–32.
pubmed: 26119945
Bikeye SN, Colin C, Marie Y, Vampouille R, Ravassard P, Rousseau A, Boisselier B, Idbaih A, Calvo CF, Leuraud P, Lassalle M, El Hallani S, Delattre JY, Sanson M. ASPM-associated stem cell proliferation is involved in malignant progression of gliomas and constitutes an attractive therapeutic target. Cancer Cell Int. 2010;10:1.
pubmed: 20142996
pmcid: 2817685
Bruning-Richardson A, Bond J, Alsiary R, Richardson J, Cairns DA, McCormack L, Hutson R, Burns P, Wilkinson N, Hall GD, Morrison EE, Bell SM. ASPM and microcephalin expression in epithelial ovarian cancer correlates with tumour grade and survival. Br J Cancer. 2011;104:1602–10.
pubmed: 21505456
pmcid: 3101901
Chen X, Wang H, Huang K, Liu H, Ding H, Zhang L, Zhang T, Yu W, He L. CT-Based Radiomics signature with machine learning predicts MYCN amplification in Pediatric Abdominal Neuroblastoma. Front Oncol. 2021;11:687884.
pubmed: 34109133
pmcid: 8181422
Chicklore S, Goh V, Siddique M, Roy A, Marsden PK, Cook GJ. Quantifying tumour heterogeneity in 18F-FDG PET/CT imaging by texture analysis. Eur J Nucl Med Mol Imaging. 2013;40:133–40.
pubmed: 23064544
Delloye-Bourgeois C, Castellani V. Hijacking of embryonic programs by neural crest-derived neuroblastoma: from physiological Migration to Metastatic Dissemination. Front Mol Neurosci. 2019;12:52.
pubmed: 30881286
pmcid: 6405627
Dissaux G, Visvikis D, Da-Ano R, Pradier O, Chajon E, Barillot I, Duverge L, Masson I, Abgral R, Santiago Ribeiro MJ, Devillers A, Pallardy A, Fleury V, Mahe MA, De Crevoisier R, Hatt M, Schick U. Pretreatment (18)F-FDG PET/CT Radiomics Predict Local Recurrence in patients treated with stereotactic body Radiotherapy for Early-Stage Non-small Cell Lung Cancer: a multicentric study. J Nucl Med. 2020;61:814–20.
pubmed: 31732678
Feng L, Lu X, Yang X, Kan Y, Sun D, Wang W, Yang J. An (18)F-FDG PET/CT radiomics nomogram for differentiation of high-risk and non-high-risk patients of the International Neuroblastoma Risk Group Staging System. Eur J Radiol. 2022;154:110444.
pubmed: 35917754
Hagemann C, Anacker J, Gerngras S, Kuhnel S, Said HM, Patel R, Kammerer U, Vordermark D, Roosen K, Vince GH. Expression analysis of the autosomal recessive primary microcephaly genes MCPH1 (microcephalin) and MCPH5 (ASPM, abnormal spindle-like, microcephaly associated) in human malignant gliomas. Oncol Rep. 2008;20:301–8.
pubmed: 18636190
Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–74.
pubmed: 21376230
Hatt M, Majdoub M, Vallieres M, Tixier F, Le Rest CC, Groheux D, Hindie E, Martineau A, Pradier O, Hustinx R, Perdrisot R, Guillevin R, El I, Naqa, Visvikis D. 18F-FDG PET uptake characterization through texture analysis: investigating the complementary nature of heterogeneity and functional tumor volume in a multi-cancer site patient cohort. J Nucl Med. 2015;56:38–44.
pubmed: 25500829
Higgins J, Midgley C, Bergh AM, Bell SM, Askham JM, Roberts E, Binns RK, Sharif SM, Bennett C, Glover DM, Woods CG, Morrison EE, Bond J. Human ASPM participates in spindle organisation, spindle orientation and cytokinesis. BMC Cell Biol. 2010;11:85.
pubmed: 21044324
pmcid: 2988714
Jensen EC. (2013) Quantitative analysis of histological staining and fluorescence using ImageJ. Anat Rec (Hoboken), 296, 378–81.
Kholodenko IV, Kalinovsky DV, Doronin II, Deyev SM, Kholodenko RV. (2018) Neuroblastoma Origin and Therapeutic Targets for Immunotherapy. J Immunol Res, 2018, 7394268.
Kim J, DeBerardinis RJ. Mechanisms and implications of metabolic heterogeneity in Cancer. Cell Metab. 2019;30:434–46.
pubmed: 31484055
pmcid: 6730674
Li C, Zhang J, Chen S, Huang S, Wu S, Zhang L, Zhang F, Wang H. Prognostic value of metabolic indices and bone marrow uptake pattern on preoperative 18F-FDG PET/CT in pediatric patients with neuroblastoma. Eur J Nucl Med Mol Imaging. 2018;45:306–15.
pubmed: 29110068
Li C, Huang S, Guo J, Wang C, Huang Z, Huang R, Liu L, Liang S, Wang H. Metabolic evaluation of MYCN-Amplified neuroblastoma by 4-[(18)F]FGln PET Imaging. Mol Imaging Biol. 2019;21:1117–26.
pubmed: 30850970
Li C, Wang S, Li C, Yin Y, Feng F, Fu H, Wang H, Chen S. Improved risk stratification by PET-based intratumor heterogeneity in children with high-risk neuroblastoma. Front Oncol. 2022;12:896593.
pubmed: 36353561
pmcid: 9637983
Marrano P, Irwin MS, Thorner PS. Heterogeneity of MYCN amplification in neuroblastoma at diagnosis, treatment, relapse, and metastasis. Genes Chromosomes Cancer. 2017;56:28–41.
pubmed: 27465929
Matthay KK, Maris JM, Schleiermacher G, Nakagawara A, Mackall CL, Diller L, Weiss WA. Neuroblastoma. Nat Rev Dis Primers. 2016;2:16078.
pubmed: 27830764
Mena E, Taghipour M, Sheikhbahaei S, Jha AK, Rahmim A, Solnes L, Subramaniam RM. Value of Intratumoral metabolic heterogeneity and quantitative 18F-FDG PET/CT parameters to predict prognosis in patients with HPV-Positive primary Oropharyngeal squamous cell carcinoma. Clin Nucl Med. 2017;42:e227–34.
pubmed: 28195905
pmcid: 5380578
Moroz V, Machin D, Hero B, Ladenstein R, Berthold F, Kao P, Obeng Y, Pearson ADJ, Cohn SL, London WB. The prognostic strength of serum LDH and serum ferritin in children with neuroblastoma: a report from the International Neuroblastoma Risk Group (INRG) project. Pediatr Blood Cancer. 2020;67:e28359.
pubmed: 32472746
Pahk K, Chung JH, Yi E, Kim S, Lee SH. Metabolic tumor heterogeneity analysis by F-18 FDG PET/CT predicts mediastinal lymph node metastasis in non-small cell lung cancer patients with clinically suspected N2. Eur J Radiol. 2018;106:145–9.
pubmed: 30150037
Pai VC, Hsu C-C, Chan T-S, Liao W-Y, Chuu C-P, Chen W-Y, Li C-R, Lin C-Y, Huang S-P, Chen L-T. ASPM promotes prostate cancer stemness and progression by augmenting Wnt-Dvl-3-β-catenin signaling. Oncogene. 2019;38:1340–53. & K. K. Tsai.
pubmed: 30266990
Park JR, Kreissman SG, London WB, Naranjo A, Cohn SL, Hogarty MD, Tenney SC, Haas-Kogan D, Shaw PJ, Kraveka JM, Roberts SS, Geiger JD, Doski JJ, Voss SD, Maris JM, Grupp SA, Diller L. Effect of Tandem Autologous Stem Cell Transplant vs single transplant on event-free survival in patients with high-risk neuroblastoma: a Randomized Clinical Trial. JAMA. 2019;322:746–55.
pubmed: 31454045
pmcid: 6714031
Perri P, Ponzoni M, Corrias MV, Ceccherini I, Candiani S, Bachetti T. (2021) A Focus on Regulatory Networks linking MicroRNAs, transcription factors and target genes in Neuroblastoma. Cancers (Basel), 13.
Pinto NR, Applebaum MA, Volchenboum SL, Matthay KK, London WB, Ambros PF, Nakagawara A, Berthold F, Schleiermacher G, Park JR, Valteau-Couanet D, Pearson AD, Cohn SL. Advances in risk classification and treatment strategies for Neuroblastoma. J Clin Oncol. 2015;33:3008–17.
pubmed: 26304901
pmcid: 4567703
Ren J, Fu Z, Zhao Y. Clinical value of (18)F-FDG PET/CT to predict MYCN gene, chromosome 1p36 and 11q status in pediatric neuroblastoma and ganglioneuroblastoma. Front Oncol. 2023;13:1099290.
pubmed: 37035169
pmcid: 10079884
Senjo H, Hirata K, Izumiyama K, Minauchi K, Tsukamoto E, Itoh K, Kanaya M, Mori A, Ota S, Hashimoto D, Teshima T, North G, Japan Hematology Study. High metabolic heterogeneity on baseline 18FDG-PET/CT scan as a poor prognostic factor for newly diagnosed diffuse large B-cell lymphoma. Blood Adv. 2020;4:2286–96.
pubmed: 32453838
pmcid: 7252551
Stauss J, Franzius C, Pfluger T, Juergens KU, Biassoni L, Begent J, Kluge R, Amthauer H, Voelker T, Hojgaard L, Barrington S, Hain S, Lynch T, Hahn K, European M. Guidelines for 18F-FDG PET and PET-CT imaging in paediatric oncology. Eur J Nucl Med Mol Imaging. 2008;35:1581–8. Association of Nuclear.
pubmed: 18536914
Tsai KK, Bae BI, Hsu CC, Cheng LH, Shaked Y. Oncogenic ASPM is a Regulatory Hub of Developmental and Stemness Signaling in Cancers. Cancer Res. 2023;83:2993–3000.
pubmed: 37384617
pmcid: 10502471
Vange P, Bruland T, Beisvag V, Erlandsen SE, Flatberg A, Doseth B, Sandvik AK, Bakke I. Genome-wide analysis of the oxyntic proliferative isthmus zone reveals ASPM as a possible gastric stem/progenitor cell marker over-expressed in cancer. J Pathol. 2015;237:447–59.
pubmed: 26178168
pmcid: 5049620
Wang WY, Hsu CC, Wang TY, Li CR, Hou YC, Chu JM, Lee CT, Liu MS, Su JJ, Jian KY, Huang SS, Jiang SS, Shan YS, Lin PW, Shen YY, Lee MT, Chan TS, Chang CC, Chen CH, Chang IS, Lee YL. A gene expression signature of epithelial tubulogenesis and a role for ASPM in pancreatic tumor progression. Gastroenterology. 2013;145:1110–20. L. T. Chen & K. K. Tsai.
pubmed: 23896173
Xie JJ, Zhuo YJ, Zheng Y, Mo RJ, Liu ZZ, Li BW, Cai ZD, Zhu XJ, Liang YX, He HC, Zhong WD. High expression of ASPM correlates with tumor progression and predicts poor outcome in patients with prostate cancer. Int Urol Nephrol. 2017;49:817–23.
pubmed: 28213802
Yoo SH, Kang SY, Cheon GJ, Oh DY, Bang YJ. Predictive role of temporal changes in Intratumoral metabolic heterogeneity during Palliative Chemotherapy in patients with Advanced Pancreatic Cancer: a prospective cohort study. J Nucl Med. 2020;61:33–9.
pubmed: 31201247
pmcid: 6954466